European Union - Finnish - EMA (European Medicines Agency)

sanofi winthrop industrie - sarilumab - niveltulehdus, nivelreuma - immunosuppressantit - kevzara yhdessä metotreksaatin (mtx) on tarkoitettu kohtalaisen ja erittäin aktiivinen nivelreuma (ra) aikuisilla, jotka ovat reagoineet riittämättömästi tai jotka eivät siedä muuttamisesta anti reumaattinen taudin hoidossa huumeet (reumalääkkeet). kevzara voidaan antaa monoterapiana jos suvaitsemattomuuden mtx tai hoidon mtx on sopimatonta.

European Union - Finnish - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatiittiautia lukuun ottamatta kortikosteroideja - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

European Union - Finnish - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - multiple myeloma - antineoplastiset aineet - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

European Union - Finnish - EMA (European Medicines Agency)

sanofi winthrop industrie - insuliini aspart - diabetes mellitus - diabeetilla käytettävät lääkkeet - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.

European Union - Finnish - EMA (European Medicines Agency)

sanofi b.v. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation; lymphoma - immunostimulantit, - mozobil on tarkoitettu käytettäväksi yhdessä granulosyytti-stimuloiva tekijä parantaa määrä hematopoeettisten kantasolujen ja ääreisverenkierron keräys-ja myöhemmin autologinen siirto potilailla lymfooma ja useita myelooma, joiden solut käyttöön huonosti.

European Union - Finnish - EMA (European Medicines Agency)

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - immunosuppressantit - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

European Union - Finnish - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - - rokotteet - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 ja 4. käyttö dengvaxia pitäisi olla virallisten suositusten mukaisesti.

European Union - Finnish - EMA (European Medicines Agency)

sanofi pasteur - hepatitis b surface antigen, diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens pertussis toxoid filamentous haemagglutinin, poliovirus (inactivated) type 1 (mahoney) type 2 (mef-1) type 3 (saukett), haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines, bacterial and viral vaccines, combined - hexacima (dtap-ipv-hb-hib) on tarkoitettu ensisijainen ja kehua rokottaminen imeväisten ja pikkulasten kuuden viikon ikäisten kurkkumätä, jäykkäkouristus, hinkuyskä, hepatiitti b, polio ja invasiiviset sairaudet haemophilus influenzae tyyppi b (hib). käyttö tämä rokote tulee virallisten suositusten mukaisesti.

European Union - Finnish - EMA (European Medicines Agency)

sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - rokotteet - hexyon (dtap-ipv-hb-hib) on tarkoitettu ensisijainen ja kehua rokottaminen imeväisten ja pikkulasten kuuden viikon ikäisten kurkkumätä, jäykkäkouristus, hinkuyskä, hepatiitti b, polio ja invasiiviset sairaudet haemophilus influenzae tyyppi b (hib). käyttö tämä rokote tulee virallisten suositusten mukaisesti.

European Union - Finnish - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - rokotteet - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 ja 5. 1 in product information document). käyttö tämä rokote tulee virallisten suositusten mukaisesti.